Cargando…

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders

Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer’s disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellomo, Giovanni, Indaco, Antonio, Chiasserini, Davide, Maderna, Emanuela, Paolini Paoletti, Federico, Gaetani, Lorenzo, Paciotti, Silvia, Petricciuolo, Maya, Tagliavini, Fabrizio, Giaccone, Giorgio, Parnetti, Lucilla, Di Fede, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044304/ https://www.ncbi.nlm.nih.gov/pubmed/33867925 http://dx.doi.org/10.3389/fnins.2021.647783

Ejemplares similares

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Microglial Heterogeneity and Its Potential Role in Driving Phenotypic Diversity of Alzheimer’s Disease
por: Sorrentino, Stefano, et al.
Publicado: (2021)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum
por: Paciotti, Silvia, et al.
Publicado: (2023)

Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers
por: Barba, Lorenzo, et al.
Publicado: (2022)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools
por: Paciotti, Silvia, et al.
Publicado: (2018)

Iatrogenic early onset cerebral amyloid angiopathy 30 years after cerebral trauma with neurosurgery: vascular amyloid deposits are made up of both Aβ40 and Aβ42
por: Giaccone, Giorgio, et al.
Publicado: (2019)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Translational Research in Alzheimer’s and Prion Diseases
por: Di Fede, Giuseppe, et al.
Publicado: (2018)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

Dreaming of a New World Where Alzheimer’s Is a Treatable Disorder
por: Catania, Marcella, et al.
Publicado: (2019)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease
por: Barschke, Peggy, et al.
Publicado: (2022)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays
por: Bellomo, Giovanni, et al.
Publicado: (2023)

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
por: Paciotti, Silvia, et al.
Publicado: (2020)

Molecular subtypes of Alzheimer’s disease
por: Di Fede, Giuseppe, et al.
Publicado: (2018)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Tackling amyloidogenesis in Alzheimer’s disease with A2V variants of Amyloid-β
por: Di Fede, Giuseppe, et al.
Publicado: (2016)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
por: Gaetani, Lorenzo, et al.
Publicado: (2018)

Lipofuscin Hypothesis of Alzheimer's Disease
por: Giaccone, Giorgio, et al.
Publicado: (2011)

Spontaneous intracerebral haemorrhage associated with early-onset cerebral amyloid angiopathy and Alzheimer’s disease neuropathological changes five decades after cadaveric dura mater graft
por: Milani, Riccardo, et al.
Publicado: (2023)

The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients
por: Nuzzo, Tommaso, et al.
Publicado: (2019)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
por: Tambasco, Nicola, et al.
Publicado: (2022)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kf8hudqkfd41bev38l8b2ipbs3